PDUFA Action Date for Hansa Biopharma's Imlifidase BLA Set for December 19, 2026

Hansa Biopharma AB

If approved, imlifidase will be the first treatment to address highly sensitized patients awaiting kidney transplantation. View original content:https://www.prnewswire.co.uk/news-releases/pdufa-action-date-for-hansa-biopharmas-imlifidase-bla-set-for-december-19-2026-302704610.html